A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study

Author： Pappo Alberto S.   Vassal Gilles   Crowley John J.   Bolejack Vanessa   Hogendoorn Pancras C. W.   Chugh Rashmi   Ladanyi Marc   Grippo Joseph F.   Dall Georgina   Staddon Arthur P.   Chawla Sant P.   Maki Robert G.   Araujo Dejka M.   Geoerger Birgit   Ganjoo Kristen   Marina Neyssa   Blay Jean-Yves   Schuetze Scott M.   Chow Warren A.   Helman Lee J.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|16|2448-2456

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.16, 2014-08, pp. : 2448-2456

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy

By  

Current Drug Targets, Vol. 15, Iss. 7, 2014-06 ,pp. : 674-680

Bentham Science Publishers

Access to resources Recommend Favorite

Insulin-like Growth Factor-1 Receptor (IGF-1R) Kinase Inhibitors in Cancer Therapy: Advances and Perspectives

By  

Current Pharmaceutical Design, Vol. 18, Iss. 20, 2012-07 ,pp. : 2901-2913

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma

By Chawla Sant P.   Chua Victoria S.   Hendifar Andrew F.   Quon Doris V.   Soman Neelesh   Sankhala Kamalesh K.   Wieland D. Scott   Levitt Daniel J.  

Cancer, Vol. 121, Iss. 4, 2015-02 ,pp. : 570-579

Blackwell Publishing

Access to resources Recommend Favorite

Recent Advancements in Small Molecule Inhibitors of Insulin–like Growth Factor-1 Receptor (IGF-1R) Tyrosine Kinase as Anticancer agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 5, 2013-04 ,pp. : 653-681

Bentham Science Publishers

Access to resources Recommend Favorite

Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study

By LoRusso Patricia   Krishnamurthi Smitha   Youssoufian Hagop   Hall Nancy   Fox Floyd   Dontabhaktuni Aruna   Grebennik Dmitri   Remick Scot  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 303-311

Springer Publishing Company

Access to resources Recommend Favorite